RT Journal Article
SR Electronic
T1 Prenatal Pb exposure is associated with reduced abundance of beneficial gut microbial cliques in late childhood: an investigation using Microbial Co-occurrence Analysis (MiCA)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.18.23290127
DO 10.1101/2023.05.18.23290127
A1 Midya, V
A1 Lane, JM
A1 Gennings, C
A1 Torres-Olascoaga, LA
A1 Wright, RO
A1 Arora, M
A1 Téllez-Rojo, MM
A1 Eggers, S
YR 2023
UL http://medrxiv.org/content/early/2023/05/24/2023.05.18.23290127.abstract
AB Background Many analytical methods used in gut microbiome research focus on either single bacterial taxa or the whole microbiome, ignoring multi-bacteria relationships (microbial cliques). We present a novel analytical approach to identify multiple bacterial taxa within the gut microbiome of children at 9-11 years associated with prenatal Pb exposure.Methods Data came from a subset of participants (n=123) in the Programming Research in Obesity, Growth, Environment and Social Stressors (PROGRESS) cohort. Pb concentrations were measured in maternal whole blood from the second and third trimesters of pregnancy. Stool samples collected at 9-11 years old underwent metagenomic sequencing to assess the gut microbiome. Using a novel analytical approach, Microbial Co-occurrence Analysis (MiCA), we paired a machine-learning algorithm with randomization-based inference to first identify microbial cliques that were predictive of prenatal Pb exposure and then estimate the association between prenatal Pb exposure and microbial clique abundance.Results With second-trimester Pb exposure, we identified a 2-taxa microbial clique that included Bifidobacterium adolescentis and Ruminococcus callidus, and a 3-taxa clique that added Prevotella clara. Increasing second-trimester Pb exposure was associated with significantly increased odds of having the 2-taxa microbial clique below the 50th percentile relative abundance (OR=1.03,95%CI[1.01-1.05]). In an analysis of Pb concentration at or above vs. below the United States and Mexico guidelines for child Pb exposure, odds of the 2-taxa clique in low abundance were 3.36(95%CI[1.32-8.51]) and 6.11(95%CI[1.87-19.93]), respectively. Trends were similar with the 3-taxa clique but not statistically significant.Discussion Using a novel combination of machine-learning and causal-inference, MiCA identified a significant association between second-trimester Pb exposure and reduced abundance of a probiotic microbial clique within the gut microbiome in late childhood. Pb exposure levels at the guidelines for child Pb poisoning in the United States, and Mexico are not sufficient to protect against the potential loss of probiotic benefits.Graphical Abstract Competing Interest StatementMA is an employee and equity holder of Linus Biotechnology Inc., a start-up company of Mount Sinai Health System. The company develops tools for the detection of autism spectrum disorder and related conditions. The following authors report no competing interests: VM, JML, CG, LATO, ROW, MMTR, SE.Funding StatementThis work was supported by the National Institute of Environmental Health Sciences (K99ES032884, P30ES023515, R01ES013744).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Icahn School of Medicine at Mount Sinai (ISMMS) and all three committees (Research, Ethics in Research, and Biosafety) included in the IRB at the National Institute of Public Health in Cuernavaca, Mexico name gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that was used in this study can be made accessible to researchers upon appropriate request with the following restrictions to ensure the privacy of human subjects. Note that access to the data is limited due to a data sharing agreement approved by the IRB at Mount Sinai. Researchers that are interested in accessing PROGRESS data must send their resume/CV as well as CITI training certificates to the IRB chair, Ilene Wilets (Ilene.wilets{at}mssm.edu). They must also submit a data analysis plan to the Principal Investigators for PROGRESS; Robert O. Wright (robert.wright{at}mssm.edu), Martha Tellez-Rojo (mmtellez{at}insp.mx), and Andrea Baccarelli (andrea.baccarelli{at}columbia.edu). Once this process is completed, the PROGRESS data analyst, Nia McRae (nia.x.mcrae{at}mssm.edu) will send a de-identified dataset via Box, a secure data sharing platform.